Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MeiraGTx Holdings PLC (MGTX : NSDQ)

• Company Description    MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, AAV-AQP1 and AAV-UPF1 which are in clinical stage. MeiraGTx Holdings plc is based in New York. Number of Employees: 381

• Price / Volume Information    Yesterday's Closing Price: $7.61 Daily Weekly Monthly 20 Day Moving Average: 298,864 shares Shares Outstanding: 80.45 (millions) Market Capitalization: $612.20 (millions) Beta: 1.29 52 Week High: $8.98 52 Week Low: $3.94 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.64% -10.25% 12 Week 17.44% 6.68% Year To Date 24.96% 12.45%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 450 East 29th Street 14th Floor - NEW YORK,NY 10016 USA ph: 646-860-7985 fax: - investors@meiragtx.com http://www.meiragtx.com

• General Corporate Information    Officers Alexandria Forbes - Chief Executive Officer;President and Director Keith R. Harris - Chairman of the Board and Director Richard Giroux - Chief Financial Officer Ellen Hukkelhoven - Director Lord Mendoza - Director Peer Information MeiraGTx Holdings PLC (CORR.) MeiraGTx Holdings PLC (RSPI) MeiraGTx Holdings PLC (CGXP) MeiraGTx Holdings PLC (BGEN) MeiraGTx Holdings PLC (GTBP) MeiraGTx Holdings PLC (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G59665102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 80.45 Most Recent Split Date: (:1) Beta: 1.29 Market Capitalization: $612.20 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.51 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.86 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 39.13% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 206.61 Price/Cash Flow: - Price / Sales: 16.15 EPS Growth vs. Year Ago Period: 36.84% vs. Previous Quarter: 5.88% Sales Growth vs. Year Ago Period: 1,208.87% vs. Previous Quarter: 91.64% ROE 06/30/25 - -314.44 03/31/25 - -241.05 12/31/24 - -192.95 ROA 06/30/25 - -63.28 03/31/25 - -62.93 12/31/24 - -61.56 Current Ratio 06/30/25 - 0.88 03/31/25 - 1.53 12/31/24 - 2.03 Quick Ratio 06/30/25 - 0.88 03/31/25 - 1.51 12/31/24 - 2.03 Operating Margin 06/30/25 - -413.85 03/31/25 - -483.21 12/31/24 - -529.54 Net Margin 06/30/25 - -415.39 03/31/25 - -484.90 12/31/24 - -444.10 Pre-Tax Margin 06/30/25 - -415.39 03/31/25 - -484.90 12/31/24 - -444.10 Book Value 06/30/25 - 0.04 03/31/25 - 0.41 12/31/24 - 0.87 Inventory Turnover 06/30/25 - 85.28 03/31/25 - 101.49 12/31/24 - 247.18 Debt-to-Equity 06/30/25 - 26.29 03/31/25 - 2.34 12/31/24 - 1.19 Debt-to-Capital 06/30/25 - 96.34 03/31/25 - 70.10 12/31/24 - 54.35

Powered by Zacks Investment Research ©